Russell Cohen, MD
Dermatology · Oceanside, NYNPI 1538167242
Payments from drug & device makers
Across 2,328 payments — averaging $992.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$277K
- Incyte Corporation$245K
- AbbVie$229K
- Sanofi$191K
- Amgen$182K
- Regeneron Healthcare Solutions, Inc.$166K
- plus $1M from 24 others
Across 15 payments — averaging $3726.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$56K
What the payments were for
- Consulting fees$80,2094%
- Speaking & faculty fees$1,791,88886%
- Travel & lodging$149,8917%
- Food & beverage$61,1723%
- Education$4540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 88 | $277,412 |
| Incyte Corporation | 281 | $244,787 |
| AbbVie(2 entities) | 294 | $228,609 |
| Sanofi | 127 | $190,678 |
| Amgen | 148 | $182,224 |
| Regeneron Healthcare Solutions, Inc. | 135 | $165,733 |
| Johnson & Johnson | 133 | $163,162 |
| UCB, Inc. | 174 | $156,186 |
| E.r. Squibb & Sons, L.L.C. | 122 | $127,193 |
| Dermavant Sciences, Inc. | 103 | $123,559 |
| Lilly USA, LLC | 117 | $91,386 |
| Novartis | 109 | $79,693 |
| Sun Pharmaceutical Industries Inc. | 65 | $57,182 |
| Janssen Scientific Affairs, LLC | 43 | $52,715 |
| Arcutis Biotherapeutics, Inc. | 56 | $40,963 |
| Bristol Myers Squibb | 44 | $26,404 |
| Galderma Laboratories, L.p. | 28 | $23,678 |
| Botanix SB Inc | 22 | $23,634 |
| Organon | 23 | $22,343 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 39 | $21,249 |
| LEO Pharma Inc. | 162 | $6,231 |
| Regeneron | 5 | $4,862 |
| Journey Medical Corporation | 1 | $147 |
| Sanofi-aventis U.S. LLC | 1 | $137 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $44 |
| Boehringer Ingelheim | 1 | $23 |
| Mylan Pharmaceuticals Inc. | 1 | $21 |
| EPI Health, LLC | 1 | $17 |
| Biofrontera Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,310,325 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 79 | $309,758 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $260,048 |
| Humira PenAdalimumab | 19 | $248,049 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 26 | $210,153 |
| TremfyaGuselkumab | 15 | $202,418 |
| Dupixent SyringeDupilumab | 24 | $123,312 |
| OpzeluraRuxolitinib Phosphate | 22 | $43,104 |
| VtamaTapinarof | 24 | $32,488 |
| Clobetasol Propionate | 131 | $6,501 |
| Tretinoin | 46 | $3,825 |
| Fluocinonide | 75 | $3,749 |
| Triamcinolone Acetonide | 205 | $3,347 |
| Fluorouracil | 54 | $3,156 |
| Mometasone Furoate | 127 | $2,448 |
| Halobetasol Propionate | 30 | $1,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $163,162 | $202,41815 claims |
| Incyte CorporationOpzelura | $244,787 | $43,10422 claims |
| Dermavant Sciences, Inc.Vtama | $123,559 | $32,48824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.
Other dermatology in Oceanside
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- John TuRochester$5.4M
- Jeffrey WeinbergKew Gardens$4.9M
- Neil SadickNew York$4.2M
- Alice GottliebSomers$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.